Sanofi’s tolebrutinib is receiving a regulatory lift in Europe after the FDA rejected the drug due to safety concerns, according to reports. The Committee for Medicinal Products for Human Use (CHMP) issued a positive recommendation for approval for a specific type of multiple sclerosis, setting up the therapy for its first European authorization. The update follows Sanofi’s complete response letter from the FDA in December, which stalled U.S. progress. The European recommendation effectively creates a second attempt pathway for tolebrutinib, and may affect competitive positioning among MS BTK strategies across global markets. For developers and investors tracking MS BTK inhibitors, the case highlights how safety signal interpretation and trial endpoints can translate differently depending on regulator-specific requirements and the patient population under review.